(a) New drugs and biological products (1) In general (A) General requirements Except with respect to an application for which subparagraph (B) applies, a person that submits, on or after September 27, 2007, an application (or supplement to an application) for a drug- (i) under section 355 of this title for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration; or (ii) under section 262 of title 42 for a new active ingredient, new indication,
I. Section 201.66 Standard Labeling Format A. Overall 1. The "Drug Facts" labeling is set off in a box or similar enclosure by the use of a barline with all black type printed on a white, color contrasting background. B. Typeface and size 1. "Drug Facts" is set in 14 point Helvetica Bold Italic, left justified. 2. "Drug Facts (continued)" is set in 8 point Helvetica Bold Italic for the words "Drug Facts" and 8 point Helvetica Regular for the word "(continued)" and is left justified. 3. The headings
(a) Only the applicant may submit a supplement to an application. (b) All procedures and actions that apply to an application under § 314.50 also apply to supplements, except that the information required in the supplement is limited to that needed to support the change. A supplement is required to contain an archival copy and a review copy that include an application form and appropriate technical sections, samples, and labeling; except that a supplement for a change other than a change in labeling
(a)Duration of prescription requirement. Any drug limited to prescription use under section 503(b)(1)(B) of the act remains so limited until it is exempted as provided in paragraph (b) or (e) of this section. (b)Prescription-exemption procedure for drugs limited by a new drug application. Any drug limited to prescription use under section 503(b)(1)(B) of the act shall be exempted from prescription-dispensing requirements when the Commissioner finds such requirements are not necessary for the protection